National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.

ABSTRACT:

Importance

Many cancer drugs are approved under the US Food and Drug Administration (FDA) accelerated approval pathway based on preliminary evidence. It is unclear how this limited evidence is integrated into the National Comprehensive Cancer Network (NCCN) guidelines, which are common references for clinicians and are used by public and private payers to determine reimbursement for oncology treatments.

Objective

To analyze the NCCN guidelines' assessments for cancer drug indications that received FDA accelerated approval compared with cancer drug indications that received FDA regular approval.

Design, setting, and participants

This cross-sectional study analyzes FDA-approved indications for cancer drugs that were granted accelerated approval from program inception in

SUBMITTER: Cliff ERS 

PROVIDER: S-EPMC10646727 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature